Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of US$ 100/kg
Request Sample
Diamond Member Since 2024

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Importers and Exporters
The supplier has import and export rights
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Fast Delivery
The supplier can deliver the goods within 15 days
Low MOQ
The MOQ for the supplier's products is 1
to see all verified strength labels (7)
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
  • Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
Find Similar Products

Basic Info.

Model NO.
HB-Favipiravir
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Children, Adult
State
Powder
Purity
>99%
Appearance
White Powder
Assay
99%
Grade
Food Grade
Place of Origin
Shaanxi, China
Package
25kg/Bag
Storage
Cool Dry Place
Transport Package
25kg/Bag
Specification
99%
Trademark
HAIBO
Origin
China
HS Code
0000
Production Capacity
99999kg/Weeks

Product Description

Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B

Favipiravir, 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.

Function and Application of Favipiravir CAS 259793-96-9
1.  Favipiravir is used for the treatment of advanced Ebola virus infection in a small animal model. It suppressed the replication of Zaire Ebola virus and prevented a lethal outcome in 100% of the animals. Based on the studies, Favipiravir can be a candidate for the treatment of Ebola hemorrhagic fever. Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, rabies virus and now COV ID-
2. Famipiravir is used in the antiviral treatment of influenza A and B. Studies have shown that, in addition to influenza viruses, the drug exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, sandy virus, Bunyavirus and rabies virus.


Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B

Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B
 
Analysis
Specification
Result
Test method
Physical Description
 
 
 
Appearance
White Powder
   White Powder
Visual
Odor
Characteristic
Characteristic
Organoleptic
Particle size
90% pass 80 mesh
90% pass 80 mesh
80 Mesh Screen
Chemical Tests
 
 
 
Assay (Lutein)
99%
90.15%
HPLC
Loss on drying
5.0% Max
1.82%
5g/105ºC/2hrs
Ash Contents
5.0% Max
1.12%
2g/525ºC/3hrs
Residual Solvents
50.0 ppm, Only Ethanol
<30.0 ppm
/
Heavy metals
5.0 ppm Max
<3.0 ppm
AAS
Lead
3.0 ppm Max
<1.0 ppm
AAS
Arsenic
3.0 ppm Max
<1.0 ppm
AAS
Microbiology Control
 
 
 
Total Bacteria Count
1,000cfu/g Max
<280cfu/g
AOAC
Yeast & Mold
100cfu/g Max
<10cfu/g
AOAC
Coliform
30.0 MPN/g Max
<3.0 MPN/g
AOAC
Conclusion
Complies with the standards.
General Status
Non-GMO, ISO Certificated.
Puya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and BPuya Supply Favipiravir CAS 259793-96-9 Treatment of Influenza a and B

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier